# SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)

> **NCT00093951** · PHASE2 · COMPLETED · sponsor: **Saegis Pharmaceuticals** · enrollment: 280 (—)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** SGS742

## Key facts

- **NCT ID:** NCT00093951
- **Lead sponsor:** Saegis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 280 (—)
- **Last updated:** 2009-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093951, "SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00093951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*